Drug Profile
Research programme: BET bromodomain inhibitors - Aurigene Oncology
Alternative Names: Pan BET bromodomain inhibitors programme - Aurigene Oncology; Selective BET bromodomain inhibitors programme - Aurigene OncologyLatest Information Update: 15 Jan 2024
Price :
$50
*
At a glance
- Originator Aurigene Discovery Technologies
- Developer Aurigene Oncology; Orion
- Class Small molecules
- Mechanism of Action Bromodomain and extraterminal domain protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 28 Nov 2018 No recent reports of development identified for preclinical development in Cancer in India (PO)
- 08 Sep 2016 Preclinical development is ongoing for Cancer (Aurigene Discovery Technologies pipeline, September 2016)
- 16 Jul 2016 No recent reports of development identified for preclinical development in Cancer in India (PO)